LAUSR

patient. South Med J. 2001;94:1021–2. 9. Faur D, García-Méndez I, Martín-Alemany N, Vallés-Prats M. Peritonitis monobacteriana por Bacteroides thetaiotaomicron en paciente en diálisis peritoneal. Nefrologia. 2012;32:679–700. 10. Chao CM, Liu WL, Lai CC. Peritoneal dialysis peritonitis caused by Bacteroides thetaiotaomicron. Perit Dial Int. 2013;33: 711–2. 11. Smans LCCJ, Souverein PC, Leufkens HGM, Hoepelman AIM, Zelissen PMJ. Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. Eur J Endocrinol. 2013;168: 609–14. 12. Cobo F, Foronda C, Pérez-Carrasco V, Martin-Hita L, GarcíaSalcedo JA, Navarro-Marí JM. First description of abdominal infection due to Alistipes ondedonkii. Anaerobe. 2000;66: 102283. https://doi.org/10.1016/j.anaerobe.2020.102283. 13. Diskin CJ. Lessons from single cell organisms: insights into the antimicrobial and toxic effects of peritoneal dialysis bases. Ther Apher Dial. 2009;14:127–35. 14. Yacoub R, Nugent M, Casi W, Nadkarni GN, Chaves LD, Abyad S, et al. Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLoS One. 2017;12(9):e0184789. https://doi.org/10.1371/journal.pone. 0184789.